Amylin: difference between revisions
Diff·revision 12 → 13·00:57, 17 Jan 2025
Difference between revision 12 and revision 13 of Amylin. 6 lines changed; the page grew by 107 bytes.
| Revision 12 — 01:42, 4 Jan 2025 CagriCass (talk) state plainly that the research-use-only form is not approved for human use 3,826 bytes +132 | Revision 13 — 00:57, 17 Jan 2025 FmocFrancis (talk) add category for the drug class 3,933 bytes +107 | ||
|---|---|---|---|
| 43 | <ref name="campbell2013">Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). PMID 23684623.</ref> | 43 | <ref name="campbell2013">Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). PMID 23684623.</ref> |
| 44 | 44 | ||
| + | 45 | == See also == | |
| + | 46 | * [[Amylin receptor agonist]] | |
| + | 47 | * [[Cagrilintide]] | |
| + | 48 | * [[CagriSema]] | |
| + | 49 | * [[Peptide aggregation]] | |
| + | 50 | ||
| 45 | {{DEFAULTSORT:Amylin}} | 51 | {{DEFAULTSORT:Amylin}} |
| 46 | [[Category:Amylin analogues]] | 52 | [[Category:Amylin analogues]] |